Browsing articles in "Bipolar Disorders"


FDA Approves Lurasidone for Pediatric Bipolar Depression
March 8, 2018   

The US Food and Drug Administration (FDA) has approved lurasidone for the treatment of bipolar depression in pediatric patients (ages 10 to 17)...
 Continue reading
Review: Benefits vs. Risks of Aripiprazole During Pregnancy
February 7, 2018   

A systematic literature search and review evaluated the available data on the use of aripiprazole during pregnancy, peripartum and lactation...
 Continue reading (Members only)
Cognitive Remediation Can Improve Cognitive Function in Bipolar Disorder
November 3, 2017   

Cognitive remediation produced significant improvements over an active control in several cognitive domains...
 Continue reading
Aripiprazole Maintena Approved for Bipolar Maintenance Treatment
August 1, 2017   

On July 28, 2017, the U.S. Food and Drug Administration approved the atypical antipsychotic Abilify Maintena (aripiprazole) as a maintenance monotherapy treatment for patients with Bipolar I disorder...
 Continue reading
FDA Update: New Warning Added to Antipsychotic Labels
April 6, 2017   

The U.S. Food and Drug Administration (FDA) has approved a labeling update for all antipsychotic medications adding a new warning to the prescribing information....
 Continue reading
Guidelines for the Recognition and Treatment of Depression with Mixed Features
March 10, 2017   

The Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) incorporated a "mixed features" specifier that recognizes the idea of mood disorders as lying on a spectrum and acknowledges the coexistence of subthreshold symptoms of (hypo)mania during a major depressive episode (or of subthreshold symptoms of depression co-occurring with a manic episode)...
 Continue reading
Consensus Statement on Use of Ketamine for Mood Disorders
March 9, 2017   

Based primarily on small-scale studies and numerous case reports, much excitement has been built around the use of ketamine in the treatment of mood disorder...
 Continue reading
Methylene Blue May Help Bipolar Depression
November 14, 2016   

In a double-blind cross over study of patients with bipolar disorder being treated with lamotrigine, an active dose (195 mg) of methylene blue was compared to a low dose (15 mg) of methylene blue which served as a placebo...
 Continue reading (Members only)
Congenital Malformations Not Seen With Antipsychotic Use During Pregnancy
September 6, 2016   

Results from a large retrospective study found that antipsychotic use during pregnancy does not significantly increase the risk of birth defects. Krista F. Huybrechts, MS, PhD and colleagues examined the association between antipsychotic (AP) use during the first trimester and the risk of congenital malformations...
 Continue reading (Members only)
Implications of a Meta-Analysis of Antidepressants for Major Depressive Disorder in Children and Adolescents
July 12, 2016   

In this comprehensive network meta-analysis, the authors analyzed the efficacy and tolerability of antidepressants in the treatment of major depressive disorder (MDD) in children and adolescents. Cipriani and colleagues reviewed the results from 34 randomized clinical trials that collectively tested treatment with 14 different antidepressants in youth (mean age 9 to 18 years) with MDD. In the analysis, only fluoxetine was superior to placebo...
 Continue reading (Members only)
Top of Page